339 related articles for article (PubMed ID: 17086138)
1. [Trends in tuberculosis treatment duration].
Veziris N; Aubry A; Truffot-Pernot C
Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
[TBL] [Abstract][Full Text] [Related]
2. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
3. [Bactericidal therapy in patients with tuberculosis].
Krasnov VA; Ursov IG
Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
[No Abstract] [Full Text] [Related]
4. [Reduced mycobacterial resistance to antituberculous drugs in the experiment and clinic: immediate and long-term results].
Belianin II; Shmelev EI
Probl Tuberk Bolezn Legk; 2007; (2):31-8. PubMed ID: 17419333
[TBL] [Abstract][Full Text] [Related]
5. Treatment duration for patients with drug-resistant tuberculosis, United States.
Winston CA; Mitruka K
Emerg Infect Dis; 2012 Jul; 18(7):1201-2. PubMed ID: 22709909
[No Abstract] [Full Text] [Related]
6. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of microchip technology in determination of drug resistance of Mycobacterium tuberculosis].
Vasil'eva IA; Chernousova LN; Zasedatelev AS; Sobolev AIu; Mikhaĭlovich VM
Probl Tuberk; 2002; (6):21-4. PubMed ID: 12227044
[TBL] [Abstract][Full Text] [Related]
8. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
Chakraborty S; Rhee KY
Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.
Morales Pérez C; Gomez-Pastrana D; Aragón Fernández C; Pérez Escolano E
Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):388-390. PubMed ID: 30635203
[No Abstract] [Full Text] [Related]
10. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
[TBL] [Abstract][Full Text] [Related]
11. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
12. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
[TBL] [Abstract][Full Text] [Related]
13. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.
Somoskovi A; Parsons LM; Salfinger M
Respir Res; 2001; 2(3):164-8. PubMed ID: 11686881
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
[TBL] [Abstract][Full Text] [Related]
15. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
16. The past, present and future of tuberculosis treatment.
Bi K; Cao D; Ding C; Lu S; Lu H; Zhang G; Zhang W; Li L; Xu K; Li L; Zhang Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):657-668. PubMed ID: 36915970
[TBL] [Abstract][Full Text] [Related]
17. [Changes in drug resistance of Mycobacteria in the simultaneous use of chemotherapy and intravenous infusions of dissolved ozone].
Belianin II; Shmelev EI
Probl Tuberk Bolezn Legk; 2004; (7):32-5. PubMed ID: 15379039
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
19. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
[TBL] [Abstract][Full Text] [Related]
20. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
Dekker TG; Lötter AP
Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
